Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Rhinomed Limited
  6. News
  7. Summary
    RNO   AU000000RNO1

RHINOMED LIMITED

(RNO)
End-of-day quote. End-of-day quote Australian Stock Exchange - 10/22
0.315 AUD   +5.00%
10/19RHINOMED : New swab takes away children's fear of swabbing
EQ
10/19PRESS RELEASE : New swab takes away children's fear of swabbing
DJ
09/28Rhinomed Limited Auditor Raises 'Going Concern' Doubt
CI
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Rhinomed Limited Reports an Important Update on Its Rhinoswab˘ Clinical Program

05/12/2021 | 07:50pm EDT

Rhinomed Limited reported an important update on its RhinoswabÔ clinical program. In December 2020 the company established that the Rhinoswab was comparable to existing standard of care nasal swabs in detecting the SARS-CoV-2 virus in RT-PCR testing. This study was undertaken at the VIDRL. Since December the company has further refined the swab technology by improving the nylon flock used on the swab. Two studies have now been completed to assess the performance of the Rhinoswab against the current commercially available standard of care nasal swab (Copan eSwabÔ). Both studies have now confirmed that the Rhinoswab outperforms the standard of care nasal swab (Copan eSwabÔ) in two critical key performance factors: capture (yield) and elution efficiency. Rhinomed's new Rhinoswab has recently been approved for sale in the Australian market and is listed on the ARTG and in the US with the FDA. The Rhinoswab standardises the collection process and makes nasal sampling easy and comfortable for users. With production underway in Melbourne, Australia the company is seeking to scale up in order to meet demand. The objective of the Nasal Swab Yield Study was to compare the mean absorption/sample capture performance of the Rhinoswab against the commercially available standard of care nasal swab (Copan eSwabÔ) at various insertion time points. Methodology: A randomised trial was conducted where 394 samples were collected from participants over a six week period. Participants were swabbed twice a day with a minimum of five hours between each sample collection. Participants were randomly assigned a nasal swab. Each swab was weighed prior to use and then weighed again post use using a calibrated Sartorius analytical scale. Participants were instructed to insert the standard of care nasal swab (Copan eSwabÔ) according to the manufacturer's Instructions for Use (15 seconds, each nostril). Participants were asked to insert the Rhinoswab according to the Rhinoswab Instructions for Use. Participants were randomly assigned one of three different time periods for insertion – 15 seconds, 60 seconds and 120 seconds. All Rhinoswabs captured a mean sample larger than the standard of care (Copan eSwabÔ) across all insertion time periods - 15 seconds, 60 seconds and 120 seconds. This study provides statistically powered evidence that the Rhinoswab, in addition to its comfort, ease of use and standardised sample collection procedure, captures a statistically larger sample from the nose than standard of care nasal swab (Copan eSwabÔ). EVALUATION OF RHINOSWAB ELUTION EFFICIENCY: Independent laboratory, Gnomix was engaged to compare the elution efficiency of the RhinoswabÔ compared to the standard of care nasal swab (Copan eSwabÔ). Methodology: An aliquot of gamma-irradiated (inactivated) SARS-CoV-2 virus (strain VIC/01/202) was received from the Victorian Infectious Diseases Reference Laboratory (VIDRL) with a nominal CT value of 18 (assay dependent). The SARS-CoV-2 virus was diluted 1/200 in a stock solution of donated saliva to represent a high virus burden sample and 1/2000 in to represent a low virus burden sample. Two protocols were followed: To reflect the standard of care, the high and low virus burden samples were applied as 4 x 5l spots (20l) onto 10 RhinoswabsÔ and 5 standard of care nasal swab (Copan eSwabÔ); and to evaluate the inherently greater potential capture area of the RhinoswabÔ in comparison to the standard of care nasal swab (Copan eSwabÔ) 4 x 8l spots (32l) were applied onto 10 RhinoswabsÔ. In both instances each swab was then placed into a 5ml tube containing 1ml of Saline, vortexed vigorously for 30 seconds and left to elute for 1 hour at room temperature. Standard curve samples were prepared by spiking 32l, 20l, 15l, 10l and 5l of the respective high and low virus burden samples into a 5ml tube containing 1ml of Saline, vortexed vigorously for 30 seconds and left to sit for 1 hour at room temperature. Following elution, 140l of eluate was extracted using the QIAamp Viral RNA Mini Kit (QIAGEN) according to the manufacturer's instructions. The QuantiNova IC RNA was included in all samples as an extraction control. Reverse transcription and qPCR were performed using the QuantiNova Pathogen +IC Kit (QIAGEN) in combination with the SARS-CoV-2 N1+N2 assay kit (QIAGEN) according to the manufacturer's instructions. A 6l volume of input viral RNA was used in the QuantiNova Pathogen Assay and thermal cycling was performed on a Rotorgene Q qPCR instrument using the conditions in the QuantiNova Pathogen +IC Kit handbook. The QuantiNova IC RNA, extraction negative control and PCR negative control were included on each run.


ę S&P Capital IQ 2021
All news about RHINOMED LIMITED
10/19RHINOMED : New swab takes away children's fear of swabbing
EQ
10/19PRESS RELEASE : New swab takes away children's fear of swabbing
DJ
09/28Rhinomed Limited Auditor Raises 'Going Concern' Doubt
CI
09/13Rhinomed Limited Appoints Rhinoswab Distributors for Australia and Belgium, the Netherl..
CI
09/10RHINOMED : to Deliver One Million COVID-19 Nasal Swabs to Australia's Victoria Government
MT
09/09Rhinomed Limited Receives an Initial Purchase Order for One Million Rhinoswabs from the..
CI
08/26Rhinomed Limited Announces Ethics Approval Granted for Clinical Trial of First Nasal Sw..
CI
08/26Rhinomed Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
08/10Rhinomed Limited Receives Purchase Orders and Begun Supplying NSW Health Pathology
CI
05/20RHINOMED : Receives CE Mark for Nasal Swab Product
MT
More news
Financials
Sales 2021 4,42 M 3,30 M 3,30 M
Net income 2021 -8,64 M -6,45 M -6,45 M
Net cash 2021 1,87 M 1,40 M 1,40 M
P/E ratio 2021 -4,55x
Yield 2021 -
Capitalization 79,9 M 59,7 M 59,7 M
EV / Sales 2020 2,37x
EV / Sales 2021 8,48x
Nbr of Employees -
Free-Float 10,1%
Chart RHINOMED LIMITED
Duration : Period :
Rhinomed Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RHINOMED LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Managers and Directors
Michael Johnson Chief Executive Officer, MD & Executive Director
Sean Slattery Chief Financial Officer & Secretary
Ronald R. Dewhurst Non-Executive Chairman
Brent J. Scrimshaw Independent Non-Executive Director
Eric Knight Independent Non-Executive Director
Sector and Competitors